Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Conditions

• Mesothelin Positive
• Stage III Non-Small Cell Lung Cancer AJCC v7
• Stage IIIA Non-Small Cell Lung Cancer AJCC v7
• Stage IIIB Non-Small Cell Lung Cancer AJCC v7
• Stage IV Non-Small Cell Lung Cancer AJCC v7

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Anetumab Ravtansine — BIOLOGICAL
  Given IV
• Atezolizumab — BIOLOGICAL
  Given IV
• Laboratory Biomarker Analysis — OTHER
  Correlative studies

Study Details

This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date

Aug 10, 2018

Status verified

Feb 2020

Primary completion

Sep 11, 2019

Completion

Jan 7, 2020

Study Design

Enrollment

1 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (anetumab ravtansine, atezolizumab)
  Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) (Phase I) [ Time Frame: Up to 21 days ]

Locations (3)

Find similar trials in Phoenix, AZ

Related Studies

• A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
  PHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey